Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 Positive T-Cell Lymphoma

Several studies have suggested that hematopoietic stem cell transplant (HSCT) may provide a cure for Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate demonstrate substantial activity against this disease.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Benoit M. Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris Isufi, Stuart Seropian, Francine Foss Source Type: research